LAVA Therapeutics Enters Material Agreement
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 8-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, regulation-fd, filing
TL;DR
LAVA Therapeutics signed a big deal, filing an 8-K on Aug 4th.
AI Summary
LAVA Therapeutics N.V. announced on August 3, 2025, that it entered into a Material Definitive Agreement. The company also disclosed information under Regulation FD and reported other events, including financial statements and exhibits. The filing was made on August 4, 2025.
Why It Matters
This filing indicates a significant development for LAVA Therapeutics, potentially impacting its business operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- August 3, 2025 (date) — Date of earliest event reported
- August 4, 2025 (date) — Filing date
- 001-40241 (company) — Commission File Number
FAQ
What is the nature of the Material Definitive Agreement entered into by LAVA Therapeutics N.V.?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on August 3, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on August 4, 2025.
What is LAVA Therapeutics N.V.'s principal executive office address?
LAVA Therapeutics N.V.'s principal executive offices are located at Yalelaan 62, Utrecht, The Netherlands, 3584.
What is LAVA Therapeutics N.V.'s telephone number?
LAVA Therapeutics N.V.'s telephone number is +31 85 016 3100.
What are the other items reported in this 8-K filing besides the material agreement?
In addition to the entry into a material definitive agreement, the filing also includes Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding LAVA Therapeutics NV.